What is the market's earnings forecast for DarioHealth next quarter?

What is DarioHealth's latest dividend and current dividend yield?

What guidance did DarioHealth's management provide for the next earnings period?

What were the key takeaways from DarioHealth's earnings call?

Did DarioHealth beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for DarioHealth year over year?

What is DarioHealth's gross profit margin?

What does DarioHealth do and what are its main business segments?

- **Multi-Condition Platform Dominance**: 50%+ new clients adopt Dario's integrated care solution, driving 80%+ non-GAAP gross margins. 
- **2026 Growth Engine**: $12.4M ARR pipeline (45+ new clients) set to launch Q1 2026, with 90%+ retention rate. 
- **Cost Efficiency**: 31% YoY opex reduction to $17.2M; targeting 10-15% further savings by early 2027. 
- **Strategic Wins**: Largest health plan deals in company history with UnitedHealthcare and Florida Blue, plus $31.9M cash runway. 
- **Emerging Pharma Opportunity**: MASH program achieves 5x-10x ROI, expanding into $10B market with recurring revenue model.

**【CEO Summary Section】**
- DarioHealth's multi-condition platform now accounts for over 50% of new clients, driven by demand for integrated care solutions. 
- Q3 2025 revenue was $5 million, reflecting a strategic shift to high-margin annual recurring revenue (ARR) model. 
- Gross margins improved to 60% (GAAP) and 80%+ (non-GAAP), with operating expenses reduced by $17.2 million (31%) year-to-date. 
- Targeting $12.4 million in new ARR for 2026, including 45+ new clients signed YTD (exceeding 2025 goal of 40). 
- 90% client retention rate underscores platform value, with 2 large health plan wins representing Dario's largest deals to date. 

**【CFO Financial Commentary】**
- Q3 2025 cash position of $31.9 million, supported by $17.5 million private placement and capital structure simplification. 
- Operating expenses down 21% Q/Q and 31% Y/Y, with further 10-15% efficiency gains expected over 12-15 months. 
- Projected cash flow breakeven by late 2026 to early 2027, driven by $69 million pipeline (50%+ in late-stage). 
- Non-GAAP gross margin remains >80%, reflecting software-led model and AI-driven efficiency. 

**【Q&A Key Highlights】**
- **UnitedHealthcare Rollout**: Dario's multi-condition solution will launch nationally in Q1 2026 via UHC's digital marketplace, targeting 50M+ members. 
- **Pipeline Execution**: 45+ new clients (90% launching Q1 2026) contribute to $12.4M ARR, with no single client >$1M. 
- **Pharma Services Growth**: Transitioning to recurring revenue model, Dario's MASH (non-alcoholic steatohepatitis) program achieved 5x-10x ROI in pilot. 
- **Government Sector Expansion**: Engaged in maternal health and rural health initiatives with federal and state partners. 
- **Risk Mitigation**: Non-renewal of a large health plan contract (Q1 2025) remains primary driver of sequential revenue decline. 
- **Efficiency Focus**: 31% YoY opex reduction reflects post-merger integration, automation, and AI adoption across operations.

DarioHealth Corp. (DRIO) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

DRIO

DRIO fundamentals

You can ask Aime